Clinical Trial Update: RWE Non-Interventional Prospective Study of Ribociclib Effectiveness and Safety in Patients With HR+/HER2- Early Breast Cancer in Saudi Arabia

View source ↗

Summary

Real-world evidence non-interventional prospective study assessing ribociclib effectiveness and safety in HR+/HER2- early breast cancer patients in Saudi Arabia…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• KISQALI (ribociclib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: HR+/HER2- Early Breast Cancer | Status: RECRUITING